China Pharma Holdings (CPHI) Net Income towards Common Stockholders (2010 - 2026)

China Pharma Holdings has reported Net Income towards Common Stockholders for 17 years, with the latest figure at -$1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 45.52% year-over-year to -$1.1 million; the trailing twelve-month figure through Mar 2026 stood at -$3.5 million (up 22.36% YoY), and the FY2025 full-year result was -$3.2 million, up 32.7% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$1.1 million, up from -$1.2 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$475976.0 in Q1 2023, with the low at -$1.4 million in Q2 2024.
• Historically, Net Income towards Common Stockholders has averaged -$948160.5 across 5 years, with a median of -$955892.0 in 2024.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders plunged 142.51% — and 2025, when it jumped 63.26%.
• China Pharma Holdings' Net Income towards Common Stockholders stood at -$1.3 million in 2022, then climbed by 2.53% to -$1.2 million in 2023, then increased by 0.63% to -$1.2 million in 2024, then grew by 0.19% to -$1.2 million in 2025, then gained by 6.46% to -$1.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$1.1 million (Q1 2026), -$1.2 million (Q4 2025), and -$651482.0 (Q3 2025), per Business Quant data.